http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101768160-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-255 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-255 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2010-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101768160-B1 |
| titleOfInvention | Oversulfated heparin for heparin-binding biomolecule delivery and preparation the same |
| abstract | The present invention relates to heparin-activated heparin, a heparin-activated biopolymer, which comprises activating heparin to produce thiolated heparin (Hep-SH), irradiating the thiolated heparin with light, -SO 3 H). In addition, it is possible to reduce the high antithrombogenic properties of heparin and to improve the stability and stability of the heparin by binding with a biomaterial such as a growth factor, There is an advantage that it can be effectively used for the delivery of biomolecules while reducing side effects such as hemorrhage caused by using heparin. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023085540-A1 |
| priorityDate | 2010-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 62.